Clinical trial
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
NCT00392444 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00392444 |
|---|---|
| Title | Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma |
| Official title | A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | sunitinib malate |
| Enrollment | 39 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Oct 26, 2006 |
| Last update posted | May 21, 2014 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: